EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Emicizumab in Previously Untreated Patients and Minimally Treated Patients With Hemophilia A: A Comparative Study Between Two International Cohorts

Sarina Levy-Mendelovich iD, Tlalit Barhod, Ivan Budnik, Jonathan Lancashire, Jesal Patel, Assaf Arie Barg iD, Einat Avishai, Rima Dardik, Tami Brutman Barazani, Tami Livnat, Jayashree Motwani, Gili Kenet

Pediatric Blood & Cancer · 2026

DOI: 10.1002/pbc.32118 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Sarina Levy-Mendelovich und 11 weiteren Autor:innen. Beteiligte Einrichtung: Sheba Medical Center, National Hemophilia Center and Thrombosis & Hemostasis Institute, Ramat Gan, Israel. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Hemorrhage. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hemophilia A (HA) is a rare bleeding disorder caused by coagulation factor VIII (FVIII) deficiency. Prophylactic FVIII replacement therapy is essential for preventing bleeds, but it carries a risk of inhibitor development, especially in previously untreated and minimally treated patients (PUPs and MTPs, respectively). Emicizumab, a bispecific monoclonal antibody that mimics FVIII function, offers a promising alternative for HA prophylaxis due to its subcutaneous administration and favorable safety profile.

Methods

This study evaluated the real‐world safety and efficacy of emicizumab prophylaxis in two international hemophilia treatment centers (HTC). The first HTC included a cohort of 22 MTPs with severe HA (FVIII

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AAntibodies, BispecificAntibodies, Monoclonal, HumanizedHemorrhageHumansMaleInfantFemaleChild, PreschoolFollow-Up StudiesFactor VIIICohort StudiesPrognosisChild

Stichwörter der Autor:innen

emicizumabhemophilia Ainfantsminimally treated patients (MTPs)previously untreated patients (PUPs)real‐world data (RWD)

Substanzen

emicizumabAntibodies, BispecificAntibodies, Monoclonal, HumanizedFactor VIII

Autor:innen und Institutionen

  • Sheba Medical Center, National Hemophilia Center and Thrombosis & Hemostasis Institute, Ramat Gan, Israel.
  • Amalia Biron Research Institute of Thrombosis & Hemostasis, Gray Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Talpiot Medical Leadership Program, Sheba Medical Center, Ramat Gan, Israel.
  • Division of Hematology/Oncology, Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA.
  • Department of Haematology, Birmingham Children's Hospital, Birmingham, UK.
  • Department of Paediatric Hematology-Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.

ORCID-Profile: Sarina Levy-Mendelovich, Assaf Arie Barg

Zitieren

APA

Levy-Mendelovich, S., Barhod, T., Budnik, I., Lancashire, J., Patel, J., Barg, A. A., Avishai, E., Dardik, R., Barazani, T. B., Livnat, T., Motwani, J., & Kenet, G. (2026). Emicizumab in Previously Untreated Patients and Minimally Treated Patients With Hemophilia A: A Comparative Study Between Two International Cohorts. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32118

Vancouver

Levy-Mendelovich S, Barhod T, Budnik I, Lancashire J, Patel J, Barg AA, et al. Emicizumab in Previously Untreated Patients and Minimally Treated Patients With Hemophilia A: A Comparative Study Between Two International Cohorts. Pediatric Blood & Cancer. 2026. doi:10.1002/pbc.32118

BibTeX
@article{LevyMendelovich2026,
  author = {Levy-Mendelovich, Sarina and Barhod, Tlalit and Budnik, Ivan and Lancashire, Jonathan and Patel, Jesal and Barg, Assaf Arie and Avishai, Einat and Dardik, Rima and Barazani, Tami Brutman and Livnat, Tami and Motwani, Jayashree and Kenet, Gili},
  title = {Emicizumab in Previously Untreated Patients and Minimally Treated Patients With Hemophilia A: A Comparative Study Between Two International Cohorts},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  doi = {10.1002/pbc.32118}
}
Kostenlos starten →